The HBV belongs to the family Hepadnaviridae. The HBV genome is about 3200 base pairs (bps) in size and is partially double stranded [1] . It is maintained in relaxed circular conformation by cohesive 5′ ends of the deoxy ribonucleic acid (DNA) strands. In addition to the complex and the compact nature of its genome, HBV also displays conspicuous genome economy by the presence of multiple overlapping open reading frames (ORFs) [2] .
Unlike other DNA viruses, HBV replication involves a critical reverse transcription step [1] . This step involves ribonucleic acid (RNA)-dependent DNA polymerase, which lacks proofreading activity leading to error-prone viral replication [2] . The rate of nucleotide substitutions per site is about 2.1 × 10 −5 per year with the mean observation period of 22 years [2] . It is postulated that hepatitis B e antigen (HBeAg)-positive carriers are more likely to transmit the virus across human generations. Under such transmission and substitution probabilities, the best conservative extrapolation reveals that HBV would have originated from the most recent common ancestor about 2300-3100 years ago [2] .
The error-prone replication acts as a major molecular factor for the emergence of genotypes and sub-genotypes [3] . Intergenotypic recombination further accentuates the evolution of HBV [3] . As a proof, genotype I is a novel tri-recombinant of genotypes A, C and G [4] . Genotype J shows high similarity with gibbon genotypes and human genotype C [5] . Hence, evolution of HBV genotypes requires comprehensive molecular investigation to understand its influence on pathogenesis and outcome of HBV infection.
Definition of HBV genotypes
HBV is classified based on the phylogenetic analyses of the complete viral genome. Degree of nucleotide divergence in the complete genome is a molecular criterion for the designation of genotypes and sub-genotypes [6] . According to standard guidelines, genotypes and sub-genotypes are designated based on 8% (inter-group) and 4% to 8% (inter-genotype) nucleotide divergence respectively [6] . HBV genotype prevalence varies geographically. To date, 10 genotypes, A through J, and 35 sub-genotypes have been identified. The prevalence of genotypes shows geographical restriction: genotype A is prevalent in Africa, India, Europe and America; genotypes B and C are widely prevalent in Asia-Pacific; genotype D is prevalent in India, Africa, Mediterranean regions and Europe; genotype E is widely prevalent in West Africa; genotype F is seen in South and Central Americas; genotype I is largely restricted to Vietnam and Laos; and genotype J is predominantly seen in Japan [6, 7] . Studies covering wide geographic regions show the predominance of genotypes A, C and D [8, 9] .
How is HBV genotyping done?
Currently several genotyping methods are available with varying performance characteristics [10] . Most of the methods target the viral DNA due to its relative stability, ubiquity, sensitivity and specificity.
Whole genome sequencing followed by phylogenetic analyses is a gold standard for HBV genotyping, which identifies predominant, novel and recombinant genotypes [11] . The data of the whole genome sequencing can be used for molecular and other in silico applications.
Inno-LiPA works on the principle of reverse hybridization and is designed to detect known, well-characterized genotypes and mixed genotypes. The analytical sensitivity of this assay varies with viral load: 100% (1000 intenational units [IU]/ mL), 90% (100 IU/mL) and 10% (≤ 10 IU/mL) [12] . Reverse dot blot assay is rapid, inexpensive, accurate and detects mixed genotypes [13] . Oligonucleotide microarray is a sensitive assay, which can detect mixed genotypes; however, it is more expensive than sequencing and real-time polymerase chain reaction (PCR) assays [14] .
Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) is a cost-effective method that can be used in large population studies. However, it can yield about 6% indeterminate results [15] . Restriction fragment mass polymorphism (RFMP) is a highly sensitive assay with the analytical detection limit of 100 copies/mL. It can also detect drug-resistant mutation (YMDD) in the background of wild-type strain. However, it requires matrix-assisted laser desorption/ionization timeof-flight (MALDI-TOF), which is expensive and technically demanding. Occurrence of single nucleotide polymorphisms (SNPs) at restriction sites can yield a spurious band pattern attenuating the sensitivity of the assay [15] .
Multiplex PCR is reliable, fast, cost-effective with 93% accuracy and amenable for large population studies; it can also detect subgenotypes. It can yield 2% to 5% indeterminate results and SNPs in primer binding sites can affect the sensitivity [16] . Real-time PCR is rapid, high throughput, and has high sensitivity, less cross-contamination and detects mixed genotypes. SNPs at primer sites affect the sensitivity of the assay [17] . Invader® assay is highly sensitive with the analytical detection limit of 10 copies of DNA/reaction. It can detect mixed genotypes with the ratio of 2-fold difference (predominant genotype: subdominant genotype [1000:10]) [18] . However, sensitivity of the assay is affected by the occurrence of SNPs and deletions in the probe binding sequences.
Serotyping is a non-molecular traditional method used for subtyping. It is simple and inexpensive and amenable to large population studies. The major pitfall of the assay is the generation of indeterminate (1.4% to 23.4%) results. However, it is superior to molecular typing in HBV-DNA-negative patients [19] .
Broad rationale for HBV genotyping
HBV infection causes a wide spectrum of liver disease. Acute infection can range from innocuous to life-threatening fulminant disease. Chronic HBV infection can progress from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma (HCC). HBV is largely non-cytopathic. As a result, immune pathogenesis is invariably determined by intricate interaction between the virus and the host [20] . Several studies consistently showed that HBV genotypes are linked to natural history, pathogenesis and evolution of disease outcomes and influence the efficacy of interferon-based antiviral treatment [21] . Hence, genotyping is essential for comprehensive understanding of the diseases caused by HBV.
Utility of HBV genotyping for the clinician

Influence of HBV genotypes on the natural history of chronic HBV infection
Clinicians need reliable and actionable data on HBV genotypes for the successful management of HBV infection. Hence, it is important to first establish the influence of genotypes on the natural history and the outcome of chronic HBV infection.
Studies have attempted to analyze the influence of HBV genotypes on the natural history of chronic HBV infection. These studies have mostly looked at association between the specific HBV genotypes and liver disease severity. A few studies from India reported that genotype D was associated with severe disease compared with genotype A [22, 23] . However, another study revealed no difference in clinical and histological severity between genotypes A and D [24] .
In a Taiwanese cohort, genotype C was associated with higher preponderance of HBeAg-positive chronic infection and reduced spontaneous HBeAg seroconversion [25] . A Spanish study showed the association between genotype A and durable remission after HBeAg seroconversion [26] . Also, patients infected with genotypes A and B had higher rates of HBsAg seroclearance than genotypes C and D [26] . In Gambia, wild-type genotype E showed propensity for breakthrough infection in vaccinated children, and immune escape mutants were rare in wild-type strain [27] . However, in Taiwanese children, breakthrough infections were predominantly associated with genotypes B and C [28] . Thus, it is reasonable to believe that HBV genotypes influence or interact with other well-known risk factors in the natural history of chronic HBV infection.
Host immune response plays a substantial role in influencing the outcome of HBV infection [20] . If this assumption is valid, 8% nucleotide divergence of the complete genome of HBV must be able to exert significant influence on the outcome of HBV infection. Though the outcome of HBV infection is multifactorial, many studies have shown the association between HBV genotypes and various outcomes of HBV infection [21] . The preponderance of genotypes A and D with chronic liver disease and the association of genotype D with more severe liver disease have been shown in Indian population [22] . Another Indian study reported the association between genotype A and severe liver disease as compared to genotype D [29] . Among Japanese patients, genotype A (23%) was associated with increased viral persistence than non-A genotype (9%) (p = 0.003) [30] . A European study also showed the higher prevalence of genotype D than genotype A with acute, self-limited HBV infection (80% vs. 10%, p < 0.01) [31] . In addition, the prevalence of genotype A was higher than genotype D in patients with chronic infection (80% vs. 11%, p < 0.1) [31] . In the context of HBV mutants, genotypes C and D have a higher frequency of basal core promoter A1762T/G1764A mutations than genotypes A and B. HBV genotypes C, D and F carry a higher lifetime risk of cirrhosis and HCC development than genotypes A and B. HBV pre-S/S gene mutations were associated with immune escape of hepatitis B immunoglobulin or vaccine-induced immunity. Mutations in the pre-S, core promoter and X regions correlated with an increased risk of cirrhosis and HCC [32] .
Taking the available evidence into consideration, it is logical to suggest that the 8% nucleotide divergence leading to genotype difference in HBV may translate into variation of immunodominant epitopes presented on the hepatocytes affecting the immunopathogenesis of the disease and the outcome.
Influence of HBV genotypes on HCC development
As multiple studies clarified the influence of HBV genotypes on the natural history and the outcome of HBV infection, it is likely that certain genotypes may increase the risk of HCC development. A study from north-eastern India showed predominance of genotype D followed by similar prevalence of genotypes A and C in HCC patients [33] . Another Indian study also reported the role of genotype D (odds ratio, OR = 1.8) and mixed genotypes (odds ratio, OR = 6.9) and higher viral load in HCC risk [34] .
Most patients who develop HCC in India have cirrhosis and hepatitis B infection. The lower incidence of HCC in patients with cirrhosis in India compared with other countries is considered an enigma [35] . Whether viral factors like HBV genotype have any role in explaining this enigma needs to be studied.
A few other studies have shown the association between genotype C infection and higher risk of cirrhosis and HCC as compared to genotype B. Notably, a large community-based Taiwanese cohort study showed an association between genotype C and higher risk of HCC as compared to genotype B (adjusted hazard ratio [HR] 2.4 [CI 1.7-3.3], p < 0.001) [36] . The higher prevalence of HCC with genotype C was directly linked to higher viral load. In particular, patients infected with genotype C with higher viral load had 26-folds higher risk of HCC than other genotypes [37] . Furthermore, Tseng et al.
(2012) on a cohort of 2688 Taiwanese patients showed an association between HCC incidence and genotype C than genotype B [38] . In addition, a few studies have elucidated the association of genotype B with HCC risk in younger age and genotype C with HCC risk in the older age [21] . Alaskan natives with genotype F had significantly increased the risk of HCC development than genotypes A-D (OR = 7.73, CI 3.69-16.4, p < 0.001) [39] .
The incidence of HCC during long-term follow up in patients infected with different HBV genotypes has been studied in Japan. In a recent study of patients chronically infected with HBV, HCC incidence was 13.4% at 10 years. In these patients, the incidence of HCC was lower in genotype B (5.3% at 10 years) than in genotype C (18.5% at 10 years) [40] . Another recent study from Japan recorded higher incidence of HCC in genotype B patients compared with genotype C during the first 20 years of follow up; however, the HCC incidence was similar in genotypes B and C, after 20 years [41] .
A nomogram to predict the risk of developing HCC in an individual who is infected with hepatitis B was developed using the REVEAL study database; it was shown to be accurate in predicting HCC development in the validation cohort. HBV genotype was one of the 8 predictive risk factors used in this nomogram. This information (ability to predict risk of HCC) may be useful to counsel patients with hepatitis B and may help clinical decision-making about starting anti-viral treatment [42] . However, as this was developed and validated in the REVEAL study from Taiwan (predominant HBV genotypes B and C), this may not be applicable to other parts of the world [43] . Similar scores/nomograms to predict risk of HCC need to be developed in other countries, incorporating HBV genotype data prevalent in the population of the region studied.
Studies have also analyzed HBV sub-genotypes and its association with HCC. Recent reports suggest that HBV sub-genotype D1 may have higher potential to cause HCC than D3 [44] .
Influence of HBV genotype on development of acute-on-chronic liver failure
Cross-sectional studies from China suggest that patients with HBV genotype B and having mutations in basal core promoter and pre-core/core regions of the HBV gene had higher predisposition to develop acute-on-chronic liver failure (ACLF) compared with the patients with HBV genotype C and wildtype basal core promoter and pre-core/core regions of the HBV gene [45, 46] .
Influence of HBV genotypes on the outcome of antiviral treatment
Current guidelines recommend two therapeutic options for chronic HBV infection that include standard/pegylated interferon (PEG-IFN) and nucleos(t)ide analogues. Many reports point towards the definite impact of HBV genotypes on interferon-based therapies [15, 47] . In contrast, response to nucleos(t)ide analogues is not significantly influenced by HBV genotype [47] .
HBV genotypes and response to interferon therapy
Host immune response plays an important role in the pathogenesis and outcome of chronic HBV infection. Interferon stimulates multiple antiviral pathways of the host. HBV genotypes may differentially influence the virus-host interaction. Several studies have shown the influence of HBV genotypes on the outcome of IFN therapy [15, 21] .
IFN treatment in HBeAg-positive patients led to higher rates of HBeAg seroconversion in patients with genotypes A and B than those with genotypes C and D [48, 49] . A multicentre study revealed that in HBeAg-positive patients, PEG-IFN treatment had varying rate of HBeAg clearance among HBV genotypes: A (47%), B (44%), C (28%) and D (25%) [50] . On further analysis, patients with genotype A had higher rates of HBsAg clearance irrespective of their HBeAg status [51] . Confirming these findings, a meta-analysis showed that genotype A was associated with greater response to IFN therapy than genotype D irrespective of HBeAg status [47] . Furthermore, in HBeAg-positive patients, genotype C predicted poorer response to IFN therapy than genotype B [47] .
During PEG-IFN therapy, in HBeAg-positive patients with genotypes B and C, HBsAg levels at week 12 (< 1500 IU/mL) correlated with HBeAg seroconversion. On the contrary, patients with high HBsAg levels at week 12 (> 20,000 IU/mL) were refractory to therapy [52] . Likewise, during PEG-IFN therapy, in HBeAg-positive patients infected with genotypes A and D, lack of change in HBsAg levels demonstrated inferior response in the form of HBeAg loss at 26 weeks after treatment [53] . In HBeAg-negative patients, the response to PEG-IFN therapy varied widely with genotypes, which can be largely categorized based on the mean reduction of HBsAg level: highest response with genotype A, intermediate with genotypes B and D and lowest with genotypes C and E. However, on further follow up, genotypes A and D showed sustained decrease and genotypes B, C and E showed variable rebound [54] .
HBV genotypes and response to nucleos(t)ide analogues
The response to nucleos(t)ide analogue therapy is largely similar among various HBV genotypes [47] . A few studies have shown the preponderance of genotype B among patients with earlier emergence and establishment of lamivudine resistance [21] . However, another study contradicted and showed the sustained responsiveness to lamivudine with genotype B than genotype C [55] . In vitro studies showed that wild-type HBV strains (genotypes A-H) and drug-resistant hepatitis B strains were susceptible to tenofovir alafenamide [56] . In chronically HBV-infected patients treated with different nucleos(t)ide analogues-lamivudine, entecavir, tenofovir (disoproxil fumarate or alafenamide fumarate)-for > 6 months (mean duration of treatment 71 months), patients with genotype B had a significantly higher cumulative rate of HBsAg loss (3.6% at 10 years) than those with genotype C (0.7% at 10 years) [40] .
In patients who are on nucleos(t)ide therapy for prolonged periods, HBV genotype may switch from one to another, probably due to treatment-induced pressure. Genotype A and mixed genotypes were more likely to switch, while the patients were treated with tenofovir, compared with genotype D [57] .
Public health importance of HBV genotyping data HBV genotypes and sub-genotypes have distinct geographical distribution. Immigration has recently become an important confounding factor of global HBV distribution and has been substantially changing the geographic pattern of HBV subgenotypes. Inter-genotype recombination can further contribute to the virus's evolutionary history. The circulation of novel recombinants and variants justifies the need to improve immune prophylaxis, diagnosis and treatment strategies.
HBV genotyping is an important tool that has been used to investigate the cause of outbreaks of hepatitis B [58] and modes of transmission [59] . When outbreaks of hepatitis B are observed as well as when newer modes of HBV transmission (for example HBV transmission via insects) are hypothesized [60] , tools like HBV genotyping are likely to be useful in investigating these.
Conclusions
Whole genome sequencing is still the preferred and gold standard method of HBV genotyping. Globally, evidence suggests that HBV genotypes influence the natural history, pathogenesis and outcomes of the infection. In particular, genotypes C and D significantly increase the risk of progression to cirrhosis and HCC development as compared with genotypes A and B. While HBV genotypes influence response to IFN therapy, they do not appear to significantly impact response to nucleos(t)ide therapy. Routine HBV genotyping as part of clinical practice is not warranted at present.
The HBV genotype landscape in India, with its multiethnic population, is likely to be diverse. Many reports from India have documented HBV genotypes in infected individuals in specific regions of the country [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] . In this context, a pan-Indian study on the regional variations in HBV genotypes in this issue of the Journal is laudable [73] . More studies in this field are needed to unravel the transmission and pathogenic mechanisms of hepatitis B and its potential implications for prevention and treatment.
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